Novel targets and therapeutics for bone loss.
Advances in the treatment of osteoporosis over the past decade have resulted in the generation of novel therapeutic agents aimed at providing both anticatabolic and anabolic effects in bone. In-depth understanding of the biology of key factors regulating bone metabolism has begun to reveal new approaches to treating this costly and debilitating disease. During the next decade we will observe the development and evolution of several new classes of therapeutic targets and agents to combat this disease.
Margolis
Ronald N
RN
Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 6707 Democracy Blvd., Room 693, Bethesda, MD 20892-5460, USA. rm76f@nih.gov
Wimalawansa
Sunil J
SJ
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001846:Bone Development; D001862:Bone Resorption / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D044162:Parathyroid Hormone-Related Protein / Q000502:physiology; D011453:Prostaglandins / Q000502:physiology; D013234:Stem Cells / Q000166:cytology / Q000502:physiology; D051153:Wnt Proteins / Q000502:physiology
D050071:Bone Density Conservation Agents; D044162:Parathyroid Hormone-Related Protein; D011453:Prostaglandins; D051153:Wnt Proteins